Mizuho raised the firm’s price target on Herbalife (HLF) to $10 from $9 and keeps a Hold rating on the shares. The company’s Pro2col acquisition and “rapid roll-out” of beta testing in Q3 mark Herbalife’s entrance into personalized nutrition, which offers a new path for volume growth, the analyst tells investors in a research note. Mizuho adds that Herbalife’s volume declines are moderating. It believes a return to volume growth is possible in fiscal 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLF:
- Herbalife: Buy Rating Affirmed Amid Mixed Traffic Signals and Potential Market Recovery
- Herbalife Ltd’s Earnings Call: Innovation Amid Challenges
- Herbalife Ltd. Reports Strong Q2 Earnings and Raises Guidance
- Herbalife Reports Q2 2025 Financial Results and Innovations
- Herbalife reports Q2 adjusted EPS 59c, consensus 50c